37 Bligh Street
SUITE 804 LEVEL 8
Sydney, NSW 2000
|Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD||Exec. Chairman||369.32k||N/A||1956|
|Ms. Leslie Chong||CEO, MD & Exec. Director||719.13k||N/A||N/A|
|Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.||Chief Technology Officer||328.88k||N/A||N/A|
|Mr. Phillip Allen Hains BBus(Acc), CA, MBA||CFO & Joint Company Sec.||N/A||N/A||1959|
|Dr. Anthony Good||Sr. VP of Clinical Research||N/A||N/A||N/A|
|Dr. Monil Shah M.B.A., Pharm.D.||Chief Bus. Officer||N/A||N/A||N/A|
|Ms. Ursula McCurry||Sr. VP of Clinical Operations||N/A||N/A||N/A|
|Mr. Nathan Jong C.A.||Joint Company Sec.||N/A||N/A||N/A|
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Imugene Limited’s ISS governance QualityScore as of 31 July 2022 is 8. The pillar scores are Audit: 4; Board: 9; Shareholder rights: 1; Compensation: 9.